Table 2.
Efficacy of AVI in adult (n = 24) and child (n = 12) patients with advanced Ewing sarcoma
| Efficacy measurements | Adult (n =24) | Children (n = 12) |
|---|---|---|
| Response at 12 weeks | ||
| Complete response | 1 (4.2%) | 4 (33.3%) |
| Confirmed partial response a | 14 (58.3%) | 6 (50.0%) |
| Stable disease | 2 (8.3%) | 0 (0.0%) |
| Progressive disease | 6 (25.0%) | 2 (16.7%) |
| ORR at 12 weeks | 62.5% | 83.3% |
| ITT failure‐free survival | ||
| KM median, months (95% CI) | 10.2 (6.0, 14.2) | 8.7 (5.1, 14.4) |
| ITT overall survival | ||
| KM median | NR | NR |
| Patients' status at last follow‐up | ||
| NED | 3 (12.5%) | 3 (25.0%) |
| AWD | 12 (50.0%) | 5 (41.7%) |
| DOD | 9 (37.5%) | 4 (33.3%) |
a
One patient received only two cycles of AVI and was evaluated as unconfirmed PR.
Abbreviations: AVI, anlotinib, vincristine, and irinotecan; AWD, alive with disease; CI, confidence interval; DOD, died of disease; ITT, intention‐to‐treat population; KM, Kaplan‐Meier; NED, no evidence of disease; NR, not reached; ORR, overall response rate.